NasdaqCM:NEO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore.


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has NeoGenomics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NEO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.7%

NEO

1.3%

US Life Sciences

3.0%

US Market


1 Year Return

55.2%

NEO

37.8%

US Life Sciences

15.8%

US Market

Return vs Industry: NEO exceeded the US Life Sciences industry which returned 38.8% over the past year.

Return vs Market: NEO exceeded the US Market which returned 15.4% over the past year.


Shareholder returns

NEOIndustryMarket
7 Day4.7%1.3%3.0%
30 Day10.8%9.2%6.0%
90 Day42.4%23.1%16.4%
1 Year55.2%55.2%38.0%37.8%18.4%15.8%
3 Year321.6%321.6%108.1%106.7%44.8%35.4%
5 Year531.1%531.1%158.3%154.9%75.7%56.7%

Price Volatility Vs. Market

How volatile is NeoGenomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NeoGenomics undervalued compared to its fair value and its price relative to the market?

6.75x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: NEO ($40.01) is trading above our estimate of fair value ($14.46)

Significantly Below Fair Value: NEO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: NEO is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: NEO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NEO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NEO is overvalued based on its PB Ratio (6.8x) compared to the US Life Sciences industry average (6.4x).


Next Steps

Future Growth

How is NeoGenomics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

122.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: NEO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NEO's is expected to become profitable in the next 3 years.

Revenue vs Market: NEO's revenue (14.9% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: NEO's revenue (14.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NEO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has NeoGenomics performed over the past 5 years?

33.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NEO is currently unprofitable.

Growing Profit Margin: NEO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NEO is unprofitable, but has reduced losses over the past 5 years at a rate of 33.4% per year.

Accelerating Growth: Unable to compare NEO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.7%).


Return on Equity

High ROE: NEO has a negative Return on Equity (-0.82%), as it is currently unprofitable.


Next Steps

Financial Health

How is NeoGenomics's financial position?


Financial Position Analysis

Short Term Liabilities: NEO's short term assets ($419.0M) exceed its short term liabilities ($61.7M).

Long Term Liabilities: NEO's short term assets ($419.0M) exceed its long term liabilities ($229.6M).


Debt to Equity History and Analysis

Debt Level: NEO's debt to equity ratio (26.1%) is considered satisfactory.

Reducing Debt: NEO's debt to equity ratio has increased from 0% to 26.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if NEO has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NEO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is NeoGenomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NEO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Doug VanOort (65 yo)

10.83yrs

Tenure

US$3,648,732

Compensation

Mr. Douglas M. VanOort, also known as Doug, has been the Chairman and Chief Executive Officer of NeoGenomics Inc. since October 28, 2009. Mr. VanOort has been the Executive Chairman and Chief Executive Off ...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD3.65M) is below average for companies of similar size in the US market ($USD5.74M).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas VanOort
Chairman & CEO10.83yrsUS$3.65m2.08%
$ 91.9m
Kathryn McKenzie
Chief Financial Officer0.50yrUS$524.84k0.0072%
$ 317.2k
George Cardoza
President of Pharma Services Divisionno dataUS$1.11m0.32%
$ 14.1m
Robert Shovlin
President of Clinical Services Division4.42yrsUS$1.28m0.13%
$ 5.9m
Lawrence Weiss
Chief Medical Officer & Chairman of Scientific Advisory Board1.58yrsUS$1.18m0.011%
$ 468.8k
Sharon Virag
Strategic Advisor1yrUS$1.20mno data
Steven Ross
VP & Chief Information Officer7.33yrsUS$508.02kno data
William Bonello
President of Informatics Division & Director of Investor Relations2.33yrsUS$820.15k0.011%
$ 482.5k
Denise Pedulla
General Counsel & Corporate Secretary1.58yrsno data0.040%
$ 1.8m
Stephanie Bywater
Chief Compliance Officer2.25yrsno datano data
Douglas Brown
Chief Strategy & Corporate Development Officer0.50yrno datano data
Marcus Silva
Chief Marketing Officer0.17yrno datano data

1.6yrs

Average Tenure

55yo

Average Age

Experienced Management: NEO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Douglas VanOort
Chairman & CEO10.83yrsUS$3.65m2.08%
$ 91.9m
Lawrence Weiss
Chief Medical Officer & Chairman of Scientific Advisory Board1.58yrsUS$1.18m0.011%
$ 468.8k
Kevin Johnson
Independent Director9.83yrsUS$167.55k0.050%
$ 2.2m
Michael Kelly
Independent Director0.083yrno data0.0016%
$ 71.1k
Raymond Hipp
Independent Director9.5yrsUS$182.56k0.12%
$ 5.5m
Bruce Crowther
Independent Director5.83yrsUS$181.76k0.044%
$ 2.0m
Steven Jones
Director16.83yrsUS$272.70k0.36%
$ 15.8m
Lynn Tetrault
Lead Independent Director0.083yrUS$183.63k0.040%
$ 1.8m
Stephen Kanovsky
Independent Director3.08yrsUS$161.87k0.0055%
$ 244.8k
Alison Hannah
Independent Director5.17yrsUS$191.56k0.071%
$ 3.2m
Rachel Stahler
Independent Director0.25yrno data0.0024%
$ 107.8k

5.2yrs

Average Tenure

63yo

Average Age

Experienced Board: NEO's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.9%.


Top Shareholders

Company Information

NeoGenomics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NeoGenomics, Inc.
  • Ticker: NEO
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.418b
  • Shares outstanding: 110.43m
  • Website: https://www.neogenomics.com

Number of Employees


Location

  • NeoGenomics, Inc.
  • 12701 Commonwealth Drive
  • Suite 9
  • Fort Myers
  • Florida
  • 33913
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NEONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2001
NG9DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2001
NEO *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 2001

Biography

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Ph ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/07 00:51
End of Day Share Price2020/08/06 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.